The Consolidated Biotech Thread 2005

Angel Biotechnology Holdings Plc
17 November 2005


For Immediate Release
17 November 2005



ANGEL BIOTECHNOLOGY HOLDINGS PLC
('Angel' or 'the Company')

First day of dealings on the AIM Market

RIC CODE : ABH.LN

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract
manufacturer, is pleased to announce its flotation today on the AIM market of
the London Stock Exchange.

Highlights of the Placing

• £1.5 million (gross) was raised via a placing of 136.36 million
ordinary shares at 1.1 p per share

• The market capitalisation at the placing price will be £6.62 million

• Angel will use the net proceeds of the placing to expand the contract
pipeline, establish a marketing presence in the US and progress the
internal drug development and research projects

• Angel's 'RIC CODE' has been lodged as ABH.LN

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc,
said: 'I am delighted that Angel has joined AIM today. The flotation will help
to raise Angel's profile in the public domain as well as provide funding for
pipeline expansion. The Company is now well positioned to be become a leading
manufacturer in the bio-pharmaceutical manufacturing market going forward.'

For further information, please call:

Angel Biotechnology Holdings plc Tel 01670 591920
Gordon Sherriff - COO Tel 07951 057016

Buchanan Communications Tel 020 7466 5000
Lisa Baderoon/Mary-Jane Johnson Mobile: 07721 413 496



About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a biomanufacturing company offering process
development services and cGMP manufacturing to support biotechnology and
pharmaceutical companies worldwide. Angel's principal activity is the
manufacture and supply of materials for use in early stage drug development and
pre-clinical studies, along with drug product and CMC documentation for Phases
I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in
pharmaceutical and biopharmaceutical manufacture, gained in companies such as
Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at
Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and listed on AIM in November 2005.


This information is provided by RNS
The company news service from the London Stock Exchange